{"filings":[{"id":68004,"accession_number":"0001437749-26-016717","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-05-13T20:05:56+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.","EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.","ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.","Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.","Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":41464000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92550,"accession_number":"0001437749-26-011116","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","9.01"],"status":"ready","headline":"Aytu BioPharma amends warrants to enable equity classification; expects liability reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended warrants from 2023 and 2025 offerings to clarify stockholder vote cannot change beneficial ownership blockers.","Prior classification as liabilities required recording a liability of $18.1M (Sep 2025) and $25.2M (Dec 2025).","Expects warrant liability reduction and equity increase by the same amount after amendment.","Issued unregistered in reliance on Section 3(a)(9) exchange and Section 4(a)(2) private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103465,"accession_number":"0001437749-26-002799","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.","Adjusted EBITDA -$0.8M vs +$1.3M, driven by EXXUA launch investments; cash $30.0M.","ADHD portfolio revenue $13.2M (down from $13.8M); pediatric $1.7M (down from $2.4M) due to marketing deemphasis.","EXXUA launched Dec 2025; initial stocking revenue $0.2M; 40+ person sales force deployed targeting $22B MDD market.","Cash and cash equivalents $30.0M, largely unchanged from $31.0M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":29053000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103464,"accession_number":"0001437749-26-001543","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.","Cash $32.6M as of 9/30/25; TTM adjusted EBITDA $6.7M; launch budget reduced from $10M to $6-8M.","Commercialization deal with Fabre-Kramer: $3M upfront, 28% base royalty plus 3% on COGS, milestones starting at $100M net sales.","Pivotal trials showed significant HAM-D17 improvement vs placebo (P=0.018 and P=0.032); no sexual dysfunction or weight gain warning.","Targeting 5,500 high-value psychiatry prescribers; 40+ person sales force; virtual team to deliver 20,000 contacts in launch phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119713,"accession_number":"0001437749-25-037389","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aytu BioPharma stockholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu with majority votes.","Grant Thornton LLP ratified as independent auditor for fiscal 2026: 5,783,905 for, 257,411 against.","Non-binding advisory vote on executive compensation approved: 3,193,511 for, 311,200 against.","Approximately 60% of outstanding shares (6,083,713) present or represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119712,"accession_number":"0001437749-25-034822","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.","ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.","Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.","Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.","EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market."],"consensus_eps_estimate":-0.5202,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":13888000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136291,"accession_number":"0001437749-25-029721","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.","Q4 net revenue $15.1M (+4% YoY); net loss $19.8M vs $4.6M prior year (incl. $18.1M impairment and derivative losses).","ADHD Portfolio net revenue $57.6M (flat YoY); Pediatric Portfolio $8.8M (+20% YoY).","Cash $31.0M at June 30, 2025; 9th consecutive quarter of positive adjusted EBITDA.","EXXUA (gepirone) for MDD launch on track for Q4 2025; entering >$22B US MDD market with novel first-in-class agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136290,"accession_number":"0001437749-25-025441","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.","Termination extinguishes all obligations under the April 21, 2021 asset purchase agreement with Rumpus.","No penalties or remaining obligations for Aytu as a result of the termination.","Clinical development of AR101 had been previously suspended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153404,"accession_number":"0001437749-25-020973","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.","Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.","Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.","Follows earlier $16.6M public offering closed earlier in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153403,"accession_number":"0001437749-25-020579","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma posts updated investor presentation highlighting EXXUA opportunity","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on June 17, 2025 for use in upcoming investor meetings.","Highlights EXXUA™ (gepirone) extended-release tablets as a key pipeline asset.","No new financial guidance, operational metrics, or material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153402,"accession_number":"0001437749-25-019868","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.","Shares outstanding post-offering: 8,976,914.","EXXUA is first-in-class oral 5HT1a receptor agonist for MDD; no sexual dysfunction warning; studied in >5,000 patients.","Conference call June 11, 2025 at 4:30 p.m. ET to detail EXXUA commercialization plan.","Net proceeds for working capital and to fund EXXUA launch; expects FDA-approved product to enter $22B U.S. MDD market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153401,"accession_number":"0001437749-25-019719","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.","Granted underwriters 30-day option to purchase up to additional 1,440,000 shares of common stock.","Net proceeds of approximately $12.9M (or $14.9M if option exercised) to be used for general corporate purposes and to exclusively commercialize EXXUA (gepirone) for major depressive disorder.","Offering expected to close June 9, 2025; Lake Street Capital Markets acting as sole book runner.","Maxim Group LLC acting as lead manager and Ascendiant Capital Markets as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153400,"accession_number":"0001437749-25-019718","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.","Royalty on net sales starts at 28%, steps up to 39% when annual net sales surpass $300M; lower tier after trigger at 24.5%-35.5%.","Milestone payments range from $5M to over $100M per year based on net sales thresholds; 10% royalty on sales above $1B.","EXXUA is a first-in-class 5HT1a receptor agonist for MDD with no sexual dysfunction label warning; launch targeted for Q4 2025.","Transaction funded by cash on hand and institutional investors including Nantahala Capital, Stonepine Capital, and Aytu management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153399,"accession_number":"0001437749-25-017989","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).","All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu; each received majority vote.","Ratification of Grant Thornton LLP as auditor for fiscal 2025 approved with 4.12M for, 134k against.","Non-binding advisory vote on executive compensation passed with 2.39M for, 268k against.","Quorum of 70% (4.33M shares) present at May 21, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153398,"accession_number":"0001437749-25-016832","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.","Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.","Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.","Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.","Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":51247000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172158,"accession_number":"0001437749-25-003563","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.","Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.","Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.","Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.","Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition."],"consensus_eps_estimate":-0.0374,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":32795000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189124,"accession_number":"0001437749-24-036630","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu settles derivative shareholder suit; court hearing Jan 13, 2025","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.","Aytu to pay $250,000 in attorneys' fees and $5,000 service award to plaintiff.","Governance enhancements include new independent board member, CEO/Chair separation, enhanced insider trading oversight.","D&O defendants released; claims against Armistice defendants preserved with Aytu remaining neutral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189123,"accession_number":"0001437749-24-034898","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.","Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.","ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.","CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.","Board separated Chairman/CEO roles; John Donofrio appointed Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":16574000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189122,"accession_number":"0001437749-24-030297","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma signs exclusive agreement with Lupin to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.","Adzenys XR-ODT and Cotempla XR-ODT are the only extended-release orally disintegrating ADHD tablets; Health Canada approval needed.","Aytu's ADHD prescriptions grew 16.5% over two years; Canadian stimulant market was $1.1B CAD (4.5M units) in 2023.","Lupin will seek regulatory approvals over 18-24 months; financial terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205619,"accession_number":"0001437749-24-030075","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)","Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M","ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1","Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025","Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205618,"accession_number":"0001437749-24-024725","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma divests Consumer Health business to private e-commerce firm; receives royalty payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.","Aytu receives revenue-based royalty payments on future sales of former Consumer Health products.","Company now focuses solely on its prescription pharmaceutical segment to drive profitability.","Wind down eliminated materially all remaining Consumer Health expenses; near adjusted EBITDA breakeven during wind-down.","Closure of Grand Prairie, TX manufacturing site expected to further enhance operating margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222556,"accession_number":"0001437749-24-021296","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aytu BioPharma annual meeting elects all directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five incumbent directors elected with majority votes; Joshua Disbrow received 2,111,846 for, 596,291 withheld.","Ratification of Grant Thornton as auditor for FY 2024 approved: 3,290,868 for, 683,165 against.","Non-binding advisory vote on executive compensation approved: 1,978,765 for, 659,394 against.","Quorum of 73% (4,037,162 shares) represented at the June 26, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222555,"accession_number":"0001437749-24-020590","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.","Interest rate reduced ~350 bps, saving ~$1.3M over loan life; maturity extended to June 2028.","Revolving credit facility extended to June 2028 with max borrowing capacity increased to $14.5M.","Received $3.5M from exercise of 2.17M warrants at $1.59; $2M used to pay down term loan.","Shares outstanding 5,972,327 as of June 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222554,"accession_number":"0001437749-24-017058","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.","ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.","Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.","TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.","Cash $19.8M; manufacturing transition expected to improve margins."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":63026000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}